Selected article for: "antiviral activity and high dose"
Author: Cáceres, C. Joaquín; Cardenas-Garcia, Stivalis; Carnaccini, Silvia; Seibert, Brittany; Rajao, Daniela S.; Wang, Jun; Perez, Daniel R.
Title: Efficacy of GC-376 against SARS-CoV-2 virus infection in the K18 hACE2 transgenic mouse model
  • Cord-id: m07m66km
  • Document date: 2021_5_5
    • ID: m07m66km
    Snippet: The COVID-19 pandemic caused by the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) is the defining global health emergency of this century. GC-376 is a M(pro) inhibitor with antiviral activity against SARS-CoV-2 in vitro. Using the K18-hACE2 mouse model, the in vivo antiviral efficacy of GC-376 against SARS-CoV-2 was evaluated. GC-376 treatment was not toxic in K18-hACE2 mice. Overall outcome of clinical symptoms and survival upon SARS-CoV-2 challenge were not improved in mice trea
    Document: The COVID-19 pandemic caused by the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) is the defining global health emergency of this century. GC-376 is a M(pro) inhibitor with antiviral activity against SARS-CoV-2 in vitro. Using the K18-hACE2 mouse model, the in vivo antiviral efficacy of GC-376 against SARS-CoV-2 was evaluated. GC-376 treatment was not toxic in K18-hACE2 mice. Overall outcome of clinical symptoms and survival upon SARS-CoV-2 challenge were not improved in mice treated with GC-376 compared to controls. The treatment with GC-376 slightly improved survival from 0 to 20% in mice challenged with a high virus dose at 10(5) TCID50/mouse. Most notably, GC-376 treatment led to milder tissue lesions, reduced viral loads, fewer presence of viral antigen, and reduced inflammation in comparison to vehicle-treated controls in mice challenged with a low virus dose at 10(3) TCID50/mouse. This was particularly the case in the brain where a 5-log reduction in viral titers was observed in GC-376 treated mice compared to vehicle controls. This study supports the notion that GC-376 represents a promising lead candidate for further development to treat SARS-CoV-2 infection and that the K18-hACE2 mouse model is suitable to study antiviral therapies against SARS-CoV-2.

    Search related documents:
    Co phrase search for related documents
    • active viral replication and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • active viral replication and load average: 1
    • active virus replication and acute respiratory: 1, 2, 3, 4, 5, 6, 7
    • active virus replication and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7
    • acute respiratory and adenosine nucleoside triphosphate analog: 1
    • acute respiratory and liver brain: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory and liver brain lung: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • acute respiratory and liver toxicity: 1, 2, 3, 4, 5
    • acute respiratory and load average: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • acute respiratory syndrome and adenosine nucleoside triphosphate analog: 1
    • acute respiratory syndrome and liver brain: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and liver brain lung: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • acute respiratory syndrome and liver toxicity: 1, 2, 3, 4
    • acute respiratory syndrome and load average: 1, 2, 3, 4, 5, 6, 7, 8
    • acute toxicity and liver brain: 1, 2, 3
    • acute toxicity and liver toxicity: 1, 2, 3